Patent intelligence · US
US 11376313
Cancer treatment
Cancer treatment
Patent details — US 11376313
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 5, 2022
- Expiration
- Jun 30, 2042
- Applicant
- Propanc Pty Ltd
- Claims
- 12
- CPC classes
- A61K, A61K2300/00, A61K38/47, A61K38/4826
Quick answer
US 11376313 (Cancer treatment) is held by Propanc Pty Ltd. Status: granted. Granted Jul 5, 2022. Expires Jun 30, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Propanc Pty Ltd
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2300/00, A61K38/47, A61K38/4826, A61P, A61P35/00
More from Propanc Pty Ltd
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11376313?
US 11376313 (Cancer treatment) is held by Propanc Pty Ltd. Status: granted. Granted Jul 5, 2022. Expires Jun 30, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11376313?
Propanc Pty Ltd is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 11376313 expire?
Our index shows an expiration date of Jun 30, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.